Top Journalists in Other Chemicals and Pharmaceuticals
Ed Silverman STAT
Pharmalot columnist and senior writer with decades covering Big Pharma; widely read for daily Pharmalittle and incisive industry commentary. Specialties: Drug pricing and access, FDA enforcement, pharma policy, corporate accountability.
Matthew Herper STAT
Senior writer for medicine and STAT events editorial lead; known for deep analysis on medical innovation and major drug stories. Specialties: Biotech pipelines, FDA decisions, R&D strategy, executive profiles.
Adam Feuerstein STAT
Senior biotech writer and co-host of The Readout LOUD; award-winning coverage of Biogen’s Aduhelm saga. Specialties: Biotech markets, clinical readouts, FDA oncology/neurology, investor sentiment.
Damian Garde STAT
Longtime national biotech reporter and Readout LOUD co-host known for agenda‑setting scoops and sharp analysis. Specialties: Biotech news and trends, Readout newsletter/podcast, venture financing.
Rebecca Robbins The New York Times
New York Times reporter focused on the pharmaceutical industry and drug policy; frequent coverage of vaccines and pricing. Specialties: Prescription drugs, vaccines, biopharma business and policy.
Author page | Email | Signal/WhatsApp
Peter Loftus The Wall Street Journal
Wall Street Journal reporter and author of The Messenger, covering drugmakers, devices and R&D developments. Specialties: Big Pharma earnings and strategy, vaccines, obesity drugs, FDA.
Riley Griffin Bloomberg News
Bloomberg health reporter covering biosecurity and government‑industry efforts against biological threats; formerly covered Big Pharma. Specialties: Biosecurity, pandemic preparedness, HHS/DoD medical countermeasures; previously U.S. pharma beats.
Robert Langreth Bloomberg News
Veteran Bloomberg science and health reporter focusing on medicines, biotech and FDA decisions. Specialties: Drug R&D, Alzheimer’s, oncology, clinical/regulatory milestones.
Anna Edney Bloomberg News
National health care reporter with a deep FDA/regulatory beat and investigations on drug and product safety. Specialties: FDA and policy, drug/device safety, consumer health regulation.
Michael Erman Reuters
Reuters correspondent covering major drugmakers and industry strategy across the U.S. market. Specialties: Big Pharma news, corporate strategy, M&A, executive interviews.
Julie Steenhuysen Reuters
Chicago‑based Reuters Health & Science correspondent frequently breaking on vaccines and U.S. public‑health guidance. Specialties: Health and science with emphasis on vaccines, infectious disease and drug policy impacts.
Hannah Kuchler Financial Times
Financial Times global pharmaceuticals editor leading FT’s life‑sciences coverage and major exclusives across Big Pharma. Specialties: Global pharma business, patent cliffs, obesity/oncology pipelines, China deals.
Sarah Neville Financial Times
FT global health editor known for award‑winning, deeply reported features connecting science, policy and patient impact. Specialties: Global health systems, long COVID, health policy and data‑driven features.
John Carroll Endpoints News
Endpoints News co‑founder and editor, a widely cited voice on biopharma deals, data and leadership trends. Specialties: Executive moves, financing cycles, pipelines, FDA politics.
Author page | Email | X/Twitter
Zachary Brennan Endpoints News
Senior editor focused on regulatory policy and the FDA, breaking news on guidance, approvals and enforcement. Specialties: FDA and global regulators, Capitol Hill, gene/cell therapy oversight.
Eric Sagonowsky FiercePharma
Executive editor at FiercePharma leading coverage across approvals, marketing, and pharma corporate strategy. Specialties: Brand strategy, launches, pricing and market access, industry rankings.
Ned Pagliarulo BioPharma Dive
Lead editor at BioPharma Dive steering day‑to‑day coverage of biotech and pharma developments and policy. Specialties: Breaking biopharma news, clinical milestones, policy shifts affecting pipelines.
Rick Mullin Chemical & Engineering News (C&EN)
C&EN senior editor covering the business of chemicals with a focus on specialty and fine‑chemicals trends. Specialties: Specialty/fine chemicals, contract manufacturing, supply chain and M&A.
Staff page | Email | X/Twitter
Alex Scott Chemical & Engineering News (C&EN)
C&EN senior editor (Europe) reporting on the EU chemicals landscape, policy and industry restructuring. Specialties: European chemicals, sustainability, trade/tariffs and plant closures.
Joseph Chang ICIS Chemical Business
Global editor of ICIS Chemical Business, leading coverage of the worldwide chemical sector and its key players. Specialties: Global commodity and specialty chemicals, executive rankings, market analysis.
PR contact | Email | Phone
Related Topics
Further Reading
Was this page helpful? We'd love your feedback — please email us at feedback@dealstream.com.